As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …

Examining and addressing unmet care needs is integral to improving the provision and
quality of cancer services. This review explored the prevalence of unmet supportive care …

Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …

Background In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole
resulted in significantly longer progression-free survival than letrozole alone among …

The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …

Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …

Background Guidelines recommend atezolizumab plus nab-paclitaxel (A+ nP) for first-line
treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer …

About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …

Summary Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant
showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced …